Physician profile
Peter Matthew Eckman
NPI 1639131345
$80,834.98
in general payments reported to CMS, 2019-2025
18 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,095 · 2020: $5,897 · 2021: $1,554 · 2022: $5,625 · 2023: $2,598 · 2024: $23K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Honoraria: $11K · Travel and Lodging: $7,059 · Food and Beverage: $6,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,623.00 |
| Honoraria | $10,550.00 |
| Travel and Lodging | $7,059.26 |
| Food and Beverage | $6,431.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $38,531.03 | 2020-2025 | Impella |
| Cvrx, INC. | $18,195.05 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $8,558.02 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Ancora Heart, INC. | $5,698.50 | 2022-2025 | Accucinch |
| Medtronic Vascular, INC. | $3,681.19 | 2019-2020 | |
| Edwards Lifesciences Corporation | $2,803.87 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,148.00 | 2024 | |
| Daxor Corporation | $458.88 | 2023-2024 | Bva-100 |
| Medtronic, INC. | $324.81 | 2021-2024 | Invos |
| Briohealth Solutions, INC. | $223.38 | 2025 | Briovad |
| Endotronix, INC. | $58.83 | 2022 | |
| Getinge USA Sales, LLC | $50.96 | 2020 | |
| Alnylam Pharmaceuticals INC. | $38.15 | 2023-2025 | Amvuttra |
| Scpharmaceuticals INC. | $34.16 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.38 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.77 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$58,400.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Eckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.